U.S. markets open in 7 hours 20 minutes
  • S&P Futures

    3,749.25
    -7.50 (-0.20%)
     
  • Dow Futures

    29,942.00
    -40.00 (-0.13%)
     
  • Nasdaq Futures

    11,515.00
    -26.75 (-0.23%)
     
  • Russell 2000 Futures

    1,757.00
    -1.10 (-0.06%)
     
  • Crude Oil

    88.36
    -0.09 (-0.10%)
     
  • Gold

    1,720.90
    +0.10 (+0.01%)
     
  • Silver

    20.84
    +0.18 (+0.87%)
     
  • EUR/USD

    0.9798
    +0.0003 (+0.03%)
     
  • 10-Yr Bond

    3.8260
    0.0000 (0.00%)
     
  • Vix

    30.52
    +1.97 (+6.90%)
     
  • GBP/USD

    1.1158
    -0.0010 (-0.09%)
     
  • USD/JPY

    144.9900
    -0.0780 (-0.05%)
     
  • BTC-USD

    19,969.15
    -302.43 (-1.49%)
     
  • CMC Crypto 200

    454.50
    -8.62 (-1.86%)
     
  • FTSE 100

    6,997.27
    -55.35 (-0.78%)
     
  • Nikkei 225

    27,125.40
    -185.90 (-0.68%)
     

Gilead Sciences to Present at Upcoming Investor Conferences

·1 min read

FOSTER CITY, Calif., August 29, 2022--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences:

Wells Fargo Healthcare Conference on Thursday, September 8 at 10:25am Eastern Time

Morgan Stanley Annual Global Healthcare Conference on Tuesday, September 13 at 10:35am Eastern Time

Baird Global Healthcare Conference on Wednesday, September 14 at 9:40am Eastern Time

The live webcasts can be accessed at the company’s investors page at investors.gilead.com. The replays will be available for at least 30 days following the presentation.

About Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.

For more information on Gilead Sciences, please visit the company’s website at www.gilead.com, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220829005663/en/

Contacts

Jacquie Ross, Investors
Investor_relations@gilead.com